Warren Foust on Scaling Visual Freedom at STAAR Surgical

Foust emphasizes that STAAR’s narrow specialization is its greatest asset. Unlike larger competitors juggling diverse product lines, the company remains laser-focused on its flagship EVO ICL, a reversible implantable lens that corrects myopia and astigmatism. According to Foust, this focused approach allows for a direct line between decision-making and patient outcomes, with an internal satisfaction rate of 99.4 percent among patients who would choose the procedure again.

While the company has expanded into more than 75 countries, Foust views overextension as the primary threat to sustainable growth. He maintains that the company’s success hinges on sequencing investments—balancing near-term performance with the longer cycles required to build surgeon confidence. In markets like China, where the technology saw early adoption, the company has refined a template for regulatory and commercial execution that it is now applying to the United States following the 2022 FDA approval.

Ultimately, Foust argues that in a specialized medical sector, science is merely the entry price. The true differentiator is trust, built through consistent product quality and reliable support for surgeons. By avoiding the urge to scale too quickly, he believes STAAR can maintain its momentum without compromising the clinical integrity that defines its brand.